[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.179.232. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1994

Ganciclovir Intraocular Device and Patient Survival

Author Affiliations

Munich, Germany

Arch Ophthalmol. 1994;112(1):20. doi:10.1001/archopht.1994.01090130029005
Abstract

Anand et al,1 in their fine article in the February 1993 issue of the Archives, describe the efficacy of an intravitreal sustained-release device containing ganciclovir to control CMV retinitis in patients with acquired AIDS. However, these authors did not report on the survival time of their 22 patients after the diagnosis of CMV retinitis.

According to the data provided by Anand et al1(p225) in Figure 1, we calculated median survival time using the Kaplan-Meier method for the 22 reported patients. Median survival time after diagnosis of CMV retinitis was 5.6 months (Figure).

In contrast, as shown by several studies, median survival time in patients treated with either intravenously administered ganciclovir or foscarnet varies between 8 and more than 12 months.2,3 Therefore, survival time in patients treated with the intravitreal sustained-release device appears to be shorter compared with patients treated with intravenously applied ganciclovir or foscarnet. In our

First Page Preview View Large
First page PDF preview
First page PDF preview
×